Research Highlight | Published:

HAEMATOLOGICAL CANCER

Alliance to iLLUMINATE the chemo-free sign

Nature Reviews Clinical Oncologyvolume 16page65 (2019) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original articles

    1. Moreno, C. et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30788-5 (2018)

    2. Woyach, J. A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1812836 (2018)

    3. Burger, J. A. et al. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood https://doi.org/10.1182/blood-2018-10-879429 (2018)

    Download references

    Author information

    Affiliations

    1. Nature Reviews Clinical Oncology

      • Diana Romero

    Authors

    1. Search for Diana Romero in:

    Corresponding author

    Correspondence to Diana Romero.

    About this article

    Publication history

    Published

    DOI

    https://doi.org/10.1038/s41571-018-0158-0

    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing